PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
- Conditions
- Hypogonadism
- Interventions
- Biological: Test formulationBiological: Reference formulation
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT03792477
- Locations
- 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸Syneos Health, Miami, Florida, United States
A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT03782662
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India
- Conditions
- Vaccines
- Interventions
- Biological: 13vPnC
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT03777865
- Locations
- 🇮🇳
Manipal Hospital / Department of Pediatrics, Bengaluru, Karnataka, India
🇮🇳KEM Hospital Research Centre, Pune, Maharashtra, India
🇮🇳Christian Medical College, Ludhiana, Punjab, India
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: PF-06865571 MonotherapyDrug: PF-05221304 MonotherapyDrug: PlaceboDrug: PF-05221304 and PF-06865571 Combination
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 99
- Registration Number
- NCT03776175
- Locations
- 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03770039
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇳🇱PRA Health Sciences Utrecht, Utrecht, Netherlands
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
- Conditions
- Lyme Borreliosis
- Interventions
- Biological: VLA15Biological: Placebo
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 572
- Registration Number
- NCT03769194
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Clinical Research Consulting, LLC, Milford, Connecticut, United States
🇺🇸United Medical Associates, Binghamton, New York, United States
Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT03765554
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
- Conditions
- Group B Streptococcus Infections
- Interventions
- Biological: PlaceboBiological: Multivalent Group B streptococcus vaccine
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1208
- Registration Number
- NCT03765073
- Locations
- 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸Velocity Clinical Research, Cincinnati, Ohio, United States
🇺🇸MedPharmics, LLC, Albuquerque, New Mexico, United States
ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03762928
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20vPnCBiological: 13vPnCOther: SalineBiological: PPSV23
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3902
- Registration Number
- NCT03760146
- Locations
- 🇺🇸
Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸Heartland Research Associates, LLC, Wichita, Kansas, United States